New filtration technologies for antibody removal from donated blood components (SANGUIS)

2011年，一项由tsb资助的可行性研究证明，开发一种新的血液过滤器的可行性，该过滤器采用了新型的“Hydrospace”纺织技术，该技术含有预封装粘合剂，用于选择性去除捐献血浆中的有害抗体。该项目将进一步开发一种强大的、高质量的、nhs批准的过滤器，它可以有效地去除足够水平的血型特异性抗体。这将使生产通用血浆成为可能，使一种血浆产品能够输注给所有血型的患者，同时保持过滤后血液成分的临床质量。通用血浆将带来临床和经济效益。一旦开发出来，我们打算血液包装制造合作伙伴将获得市场许可批准并将过滤器商业化。

The feasibility of developing a new blood filter incorporating novel 'Hydrospace' textile technology containing pre-encapsulated binders for the selective removal of harmful antibodies in donated blood plasma has been proven in a 2011 TSB-funded feasability study. This project will further develop a robust, high quality, NHS-approved filter which is effective at removing sufficient levels of blood group specific antibodies. This will enable the production of universal plasma, enabling one plasma product to be transfused to patients of all blood groups, whilst maintaining the post-filtration blood component clinical quality. A universal plasma will result in clinical and economic benefits. Once developed, we intend that the blood pack manufacturing partner will gain Marketing Authorisation Approval and commercialise the filter.